| 2005 | PIWIL2 | Upregulated | Testicular seminoma | Inhibition of apoptosis and promotion of proliferation via Stat3/Bcl-XL signaling pathway [18] |
| 2006 | PIWIL1 | Upregulated | Human gastric cancer | Cell proliferation [19] |
| 2007 | PIWIL1 | Upregulated | Soft tissue sarcoma | Stem cell proliferation [20] |
| 2008 | PIWIL1 | Up/down-regulated | Adenocarcinoma | Poor prognosis and death [21] |
| 2009 | PIWIL1 | Presence in cytoplasm | Esophageal squamous cell carcinoma | Poor prognosis [22] |
| 2010 | PIWIL2 | Varied | Cervical neoplasia | Biomarker [23] |
| 2010 | PIWIL2 | Upregulated | Human breast cancers | Biomarker [24] |
| 2011 | PIWIL1 | Upregulated | Glioma | Tumor progression, poor outcome, and biomarker [25] |
| 2011 | piR-651 | Upregulated | Gastric, colon, lung, and breast cancer | Increases cell proliferation [26] |
| 2011 | PIWIL1 | Upregulated | Colorectal cancer | Leads to poor overall survival, biomarker [27] |
| 2012 | piR-823 | Downregulated | Gastric cancer | Increases cell proliferation [28] |
| 2012 | PIWIL2 | Upregulated | Colon cancer | Metastasis [29] |
| 2013 | PIWI | Upregulated | Stage III epithelial ovarian cancer | Promotes metastasis, biomarker [30] |
| 2013 | piR-932 | Upregulated | Breast cancer | Positive regulator of breast cancer stem cells [31] |
| 2014 | PIWIL1 | Upregulated | Human breast cancer | Cell proliferation [32] |
| 2014 | piRNA-823 | Upregulated | Multiple myeloma | Regulates angiogenesis [33] |
| 2014 | PIWIL1 and PIWIL4 | Varied | Renal cell carcinoma | Related to clinicopathological parameters [34] |
| 2014 | PIWIL1 | Upregulated | Cervical cancer | Promotes chemoresistance [35] |
| 2014 | PIWIL1 | Upregulated | Hepatocellular carcinoma | Reduces proliferation and migration [36] |
| 2015 | piRNA-DQ594040 | Downregulated | Bladder cancer | Promotes cell proliferation, colony formation and functions against apoptosis [37] |
| 2015 | piR-021285 | Upregulated | Breast cancer | Epigenetic remodeling [38] |
| 2015 | PIWIL2 | Upregulated | Prostate cancer | Metastasis [39] |
| 2015 | piR-017061 | Downregulated | Pancreatic cancer | Associated with diseased condition [40] |
| 2015 | piR-015551 | Downregulated | Colorectal cancer | Associated with long ncRNA expression [41] |
| 2015 | PIWIL1 | Downregulated | Chronic myeloid leukemia | Induces growth and metastasis [42] |
| 2015 | PIWIL2 | Upregulated | Cholangiocarcinoma | Involved in shorter survival span and metastasis [43] |
| 2015 | piR-57125 | Downregulated | Renal cell carcinoma | Associated with tumor recurrence and metastasis, prognostic biomarker [44] |
| piR-30924 | Upregulated |
| piR-38756 | Upregulated |
| 2015 | PIWIL1 | Upregulated | Type 1 endometrial cancer | Tumor progression by downregulating PTEN [45] |
| 2015 | PIWIL2 | Downregulated | Bladder cancer | Related to disease specific and progression free survival [46] |
| 2016 | PIWIL4 | Upregulated | Breast cancer | Metastasis, antiapoptotic activity and proliferation[47] |
| 2016 | FR140858 | Differentially expressed | Head and neck squamous cell carcinoma | Correlated to human papillomavirus infection [48] |
| 2016 | piR-598 | Upregulated | Glioma | Induces growth and proliferation [49] |
| 2017 | PIWIL3 | Upregulated | Melanoma | Induces metastasis [50] |
| 2017 | PIWIL4 | Upregulated | Retinoblastoma | Induces proliferation [51] |
| 2018 | piR-5937 | Varied | Colon cancer | Biomarker [52] |
| piR-28876 |
| 2018 | piR-8041 | Downregulated | Glioblastoma | Related to tumor growth [53] |
| 2018 | PIWIL1 | Upregulated | Gastric cancer | Metastasis [54] |
| 2018 | PIWIL1 and PIWIL2 | Varied | Muscle invasive urothelial bladder cancer | Correlation with clinical factors, biomarkers [55] |
| 2018 | PIWIL4 | Upregulated | Human breast cancer | Cell motility [56] |
| 2019 | piR-823 | Upregulated | Multiple myeloma | Tumor progression [57] |
| 2019 | piR-39980 | Upregulated | Neuroblastoma | Tumor progression and drug resistance [58] |
| 2019 | piR-36712 | Downregulated | Breast cancer | Chemoresistance and tumor progression [59] |
| 2020 | piR-004987 | Upregulated | Lung cancer | Correlated with lung cancer from sputum as compared with normal [60] |
| piR-020809 | Upregulated |
| piR-023338 | Downregulated |
| piR-011186 | Downregulated |
| 2021 | piR-hsa-211106 | Downregulated | Lung cancer | Chemoresistance and tumor progression [61] |
| 2021 | piR-1008 | Upregulated | Lung cancer |
|
| piR-28231 | Upregulated | Lung cancer |
|
| piR-11256 | Upregulated | Lung cancer |
|
| piR-30636 | Upregulated | Lung cancer |
|
| piR-24143 | Upregulated | Lung cancer | Biomarker lung cancer [62] |
| piR-6842 | Upregulated | Lung cancer |
|
| piR-8757 | Upregulated | Lung cancer |
|
| piR-15572 | Upregulated | Lung cancer |
|
| piR-5444 | Upregulated | Lung cancer and serum exosome |
|
| piR-26925 | Upregulated |
|
|